Talus Bioscience
Talus Bioscience develops AI models and native-cell proteomics technology for drug discovery. Its Ptarmigan-1 model predicts how small molecules engage proteins without requiring a 3D structure, while MARMOT measures protein interactions and changes in living human cells, enabling researchers to investigate hard-to-drug targets such as disordered proteins and transcription factors.
Facts
- HQ
- Seattle, Washington
- Sectors
- Biotechnology Research
- Founded
- 2020
- Type
- Corporation Seattle business license
- Employees
- 24
- Registered name
- Talus Bioscience Inc Seattle business license
- Stage
- Seed
- Members see funding amounts. .
- Founders
- Alex Federation, Lindsay Pino
Is this your organization? Claim it
Talus Bio and PRISM BioLab partner to discover first-in-class small‑molecule modulators of transcription factors and PPIs using AI and PepMetics® chemistry
Talus Bio and PRISM BioLab have launched a strategic collaboration combining PRISM’s PepMetics® chemistry with Talus’s AI-guided regulome profiling to discover and optimize small-molecule modulators of transcription factors and protein–protein interactions that have resisted conventional approaches.
Talus Bio presents preclinical data showing TAL61 antitumor activity and platform validation across Brachyury, NONO, and AR‑V7 targets
Talus Bio reported preclinical data showing its regulome sequencing platform can generate drug candidates against transcription factors, with TAL61 showing anti-tumor activity in chordoma and Brachyury-positive NSCLC and additional promising compounds for NONO and AR-V7 in prostate cancer.
Talus Bio names Chris Joyce, MBA as VP of Business Development to drive pharma deals and advance TF therapeutics
Talus Bio hired Chris Joyce, MBA as VP of Business Development to accelerate pharma partnerships and advance its transcription factor therapeutics, including two programs targeting TBXT for non-small cell lung cancer and NONO-related androgen receptor splicing in castration-resistant prostate cancer.
Talus Bio launches 'Drugging the Undruggable' blog series to advocate open-source science and structure-free drug discovery
Talus Bio launched a new blog series, Drugging the Undruggable, to promote open-source computational science and explain their structure-free AI approach to targeting intrinsically disordered proteins.
Talus Bio names Gaelle Mercenne, PhD as Head of Biology to advance AI-driven transcription factor drugs
Talus Bio hires Dr. Gaelle Mercenne as Head of Biology to lead preclinical development and AI-driven lead optimization for its transcription factor therapeutics, using the MARMOT platform and funds from an $11.2M seed extension to expand its discovery team.
Talus Bioscience Raises $11.2M Seed+ Round Led by Two Bear Capital to Expand MARMOT AI Platform for Transcription Factor Therapeutics
Talus Bioscience raised $11.2M in Seed+ funding led by Two Bear Capital to expand its MARMOT AI platform that discovers and optimizes transcription factor modulators, accelerating programs targeting Brachyury-driven cancers and a prostate cancer–linked transcription factor.
Talus Bio Wins $4.3M in Grants from CARE Fund and NIH to Advance Transcription Factor Drug Development
Talus Bio secured $4.3M in non-dilutive grants — $2.3M from the Washington State Andy Hill CARE Fund and $2.0M from an NIH SBIR fast-track — to accelerate discovery of transcription factor drugs using its MARMOT proteomics platform and deep-learning models targeting childhood cancers and other diseases.
Talus Bio outlines structure-free drug discovery approach targeting intrinsically disordered proteins; pilot podcast with Dr. Lindsay Pino released
Talus Bio develops technology, AI models, and molecules to enable structure-free drug discovery focused on intrinsically disordered proteins, and a pilot episode of The Proteomics Show featuring Dr. Lindsay Pino has been released.
Talus Bio Raises $9.75M Seed Round to Advance MARMOT Platform and Appoints Michelle Briscoe as COO
Talus Bio, a Seattle biotech founded in 2020, raised $9.75 million in seed funding to advance its MARMOT platform for discovering drugs that target hard-to-drug transcription factors and hired Michelle Briscoe as COO.
Talus Bio’s Co‑founder Lindsay Pino Explains Structure‑Free AI and Regulome Profiling to Target Intrinsically Disordered Proteins
Lindsay Pino, co‑founder of Talus Bio, discusses the company’s approach to drug discovery—using large‑scale native regulome profiling and structure‑free AI models to target intrinsically disordered proteins that traditional structure‑based design can’t address.
Senior Data Scientist Joins Talus Bioscience After Postdoc and Challenging 2020 Faculty Job Market
A senior data scientist explains why they left academia to join Seattle biotech Talus Bioscience, describing their postdoc experience, the faculty job market struggles in 2020, and factors that led them to accept a startup role.
People
-
Alex Federation Executive Officer, Director, Promoter, Chief Executive Officer & Co-Founder
-
Lindsay Pino Executive Officer, Director, Chief Technology Officer & Co-Founder
-
Michelle Briscoe Executive, Executive Officer, Chief Operating Officer & Chief Financial Officer